2018 Fiscal Year Final Research Report
Identification of VEGF-dependent tumor vessels and prediction of effectiveness of bevacizumab-based therapy for colorectal cancer
| Project/Area Number |
16K08690
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
新谷 路子 (田中路子) 神戸常盤大学, 保健科学部, 准教授 (40207147)
|
|---|
| Research Collaborator |
ITOH Tomoo
OHSAKI Hiroyuki
OKAMURA Shunsuke
OSAKI Tatsushi
SHIOGAMA Kazuya
NISHIMURA Kanae
MAEDA Kotaro
MATSUOKA Hiroshi
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Keywords | 大腸癌 / 腫瘍新生血管 / チミジンキナーゼ / アポトーシス / 術前化学療法 / 予後予測 / 免疫組織化学 |
|---|
| Outline of Final Research Achievements |
We investigated the use of TK1/CD31 double immunostaining for identifying activated tumor vessels. TK1-positive vessel rate (PVR) and Ki67-PVR in colorectal cancers (CRCs) was greater than in normal tissues, whereas TK1-PVR in normal tissues was significantly less than Ki67-PVR. We also assessed whether CD31-positive vessel density (PVD), TK1-PVR, and apoptotic marker expression in CRC liver metastasis (CRCLM) after neoadjuvant chemotherapy (NAC) are associated with overall survival (OS). CD31-PVDLow were significantly associated with a longer OS. There were no deaths in patients with TK1-PVRLow tumors. Cleaved caspase-3 (CC3)High and cleaved cytokeratin-18High in tumor cells and CC3-PVRHigh were significantly associated with a shorter OS. Our results suggest that TK1/CD31 double immunostaining can detect activated tumor vessels more accurately than Ki67/CD31 staining, and analyses of tumor vessels and apoptosis in CRCLM after NAC could predict the prognosis of CRCLM patients.
|
| Free Research Field |
腫瘍病理学、免疫組織化学、臨床細胞学
|
| Academic Significance and Societal Importance of the Research Achievements |
術前化学療法を施行した大腸癌患者の肝転移巣切除材料を対象として、予後を制御する因子の発現を明らかにすることは、肝転移切除後の治療戦略を構築する上で役立つと期待される。また、予後不良の要因となる因子を標的とした治療薬の開発の構想につながる可能性がある。
|
